How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
Show Me How This Industry Could Explode!

TLX Insider Trading (Telix Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$841,500.00
Insider Selling (Last 12 Months): A$0.00

Telix Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Telix Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Telix Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/12/2020 01:00 AM ET

This chart shows the closing price history over time for TLX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
635% Growth For American Lithium Company After They Fight Back Against China
The USA is fighting an economic war with China over lithium. Until now, we've been losing (with China controlling 80% of lithium production). But this small lithium company could change that with their significant holdings in the hottest area of the US for lithium discoveries.
They've Already Seen 635% Growth In 2021

Telix Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2021Harry McCannInsiderBuy990,000A$0.85A$841,500.00
5/12/2021Christian BehrenbruchInsiderIssued100,708A$3.71A$373,626.68
11/2/2020Oliver BuckInsiderBuy165,330A$0.85A$140,530.50
5/12/2020Christian BehrenbruchInsiderIssued200,000A$1.47A$294,000.00
2/13/2020Oliver BuckInsiderBuy164,835A$0.85A$140,109.75
9/17/2019Oliver BuckInsiderBuy164,835A$0.85A$140,109.75
See Full Table
Insider Trading at Telix Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Telix Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals logo
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Read More on Telix Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

746,789 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Telix Pharmaceuticals?

Telix Pharmaceuticals' top insider shareholders include:
  1. Christian Behrenbruch (Insider)
  2. Harry McCann (Insider)
  3. Oliver Buck (Insider)
All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
Look At This Under-The-Radar Lithium Company